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Abstract 
 
Introduction: Roles of autophagy/mitophagy activation in ischemic stroke remain 
controversial. To elucidate potential reasons, we analyze the factors responsible for 
divergent results in literatures. Reactive nitrogen species (RNS) are important 
cytotoxic factors in ischemic stroke. Herein, we particularly discuss the roles played 
by RNS in autophagy/mitophagy and ischemic brain injury.   
Areas covered: Following factors should be considered in the studies on 
autophagy/mitophagy in ischemic stroke: (1) Protocols for administration of 
autophagy regulators including administration time points, routes and doses, etc.; (2) 
Specificity of autophagy regulators; (3) Animal models of cerebral ischemia with or 
without reperfusion. In the underlying mechanisms of autophagy/mitophagy, we 
particularly discuss the potential roles of RNS in mediating excessive 
autophagy/mitophagy during cerebral ischemia/reperfusion injury.  
Expert opinion: Emphasis should be given to the following aspects in future studies: 
(1) Targeting RNS and related cellular signaling pathways in the regulation of  
autophagy/mitophagy might be a promising strategy for developing novel drugs as 
well as combined therapy for thrombolytic treatment to reach better outcomes for 
ischemic stroke; (2) Developing circulating plasma biomarkers linking RNS-mediated 
autophagy/mitophagy to the magnitude of ischemic brain injury will benefit for stroke 
treatment. Subsequently, RNS could be dominant therapeutic targets to regulate 
autophagy/mitophagy for ischemic stroke.   
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1. Introduction   
Autophagy is a sophisticated catabolic process in which cytosolic contents and 
organelles are transported to lysosomes for degradation.[1] Autophagic process is 
commonly sub-typed into microautophagy, chaperone-mediated autophagy and 
marcoautophagy. In this article, we mainly discuss macroautophagy (hereafter 
referred to as autophagy), a major autophagic type for cellular self-regulation. 
Autophagy was firstly defined by C de Duve in 1960s, nearly ten years after his 
discovery of “lysosome” in rat livers.[2] Distinct from microautophagy and 
chaperone-mediated autophagy, autophagy is characterized as an evolutionary 
conserved process of ‘self-eating’ to digest defective or aggregated proteins and 
organelles via the formation of an autophagosome and its fusion with a lysosome.[3] 
Furthermore, autophagy also serves as a recycling process to support cell survival by 
reserving biosynthetic materials derived from degradation as ‘building block’ under 
energy shortage and nutrient starvation.[4] Autophagic process is a sophisticated 
intracellular regulating mechanism depending on a complex network of different 
autophagy-related (Atg) proteins. These Atg proteins participate in different phases of 
autophagy.[2] Clearly, autophagy is an ancient but sophisticated self-regulation to 
keep physiological function and defense unexpected stress and stimulus. 
Autophagy is a critical player in various physiological progress including cellular 
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growth, differentiation and homeostasis through continually turnover of dysfunctional 
proteins and organelles. Autophagic process involves initiation/induction, 
autophagosome formation and maturation/recycle.[5] Briefly, a complete autophagic 
process can be summarized into several steps: (1) Sequestration: formation of 
phagophors and sequestrating cytoplasmic constituents into autophagosomes; (2) 
Maturation: fusion of autophagosomes with lysosomes; (3) Degradation: degradation 
of autophagosomes by lysosomal hydrolases; (4) Recycle: reusing degraded 
cytoplasmic materials. With the ‘self-eating’ process, the damaged cellular 
components are degraded for cell survival under various stress conditions like 
oxidative stress, endoplasmic reticulum (ER) stress and starvation, etc.  
Central nerve system (CNS) is comparatively more vulnerable to microenvironment 
disruption than other organs. Emphasis is given to autophagy as a wise sweeper in the 
brain to maintain CNS’s physiological function.[6] Thus, CNS requires more rigorous 
quality control system including blood brain barrier (BBB) and autophagy for 
maintaining chemical hemostasis and quickly removing waste products as well as 
adapting its high demand of energy.[5] Emerging evidences point out the important 
roles of autophagy in neurodegenerative diseases (NDDs), including Alzheimer's 
disease [7], Parkinson's disease [8], Huntington's disease [9], and amyotrophic lateral 
sclerosis [10]. Dysregulation of autophagy in NDDs has been intensively studied and 
reviewed in literatures [11, 12] and targeting autophagy becomes a promising strategy 
for seeking therapeutic drug candidates for NDDs [13]. Obviously, autophagy 
becomes a hot research field in NDDs. 
 5 
Autophagy is also an important pathophysiological process in stroke. The roles of 
autophagy-lysosomal system in hemorrhagic stroke have been discussed in a recent 
review article.[14] Herein, we mainly discuss the roles and underlying mechanisms of 
autophagy in ischemic stroke. Autophagic flux can be triggered by ischemia stress, 
but its roles in ischemic stroke is still controversial.[15] Autophagy can be classified 
into basal and induced autophagy: Basal autophagy is a ‘housekeeping’ process in 
neurons [16] whereas induced autophagy possesses double-edged effects on neurons 
[17]. Multiple autophagic protein markers such as Beclin 1 
and LC3-phosphatidylethanolamine conjugate (LC3-II) were found to be robustly 
increased in cerebral ischemia animal models.[18] Also, autophagososmes and 
autolysosomes were directly found in ischemic areas by transmission electron 
microscopy.[19, 20] However, the roles of autophagy in ischemic brain injury remain 
controversial. Series of investigations indicate that autophagy like a double-edged 
sword, possesses both beneficial and detrimental effects to the brain after ischemia 
stimulus.[21]  
Recent progress draws an attention to the roles of free radicals in regulating 
autophagy in ischemic stroke. Redox homeostasis is essential for maintaining 
physiological functions through an equilibrium between antioxidant and oxidant 
levels. Imbalance of redox often results in oxidative/nitrosative stress which mediates 
dysregulation of autophagy, leading to pathological process in neurodegeneration.[22] 
Free radicals including reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) are major pro-oxidants during oxidative/nitrosative stress. Among them, 
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superoxide anions (O2
•−) is a precursor for other types of ROS, including hydrogen 
peroxide, hydroxyl radical, hypochlorous acid, and hydroperoxyl radical. Besides, 
nitric oxide (NO) and peroxynitrite anion (ONOO
-
) are two representative species of 
RNS. NO is mainly produced from L-arginine and oxygen catalyzed by various nitric 
oxide synthases (NOS). In presence of O2
•−, NO can rapidly react with O2
•− to 
generate ONOO
-
.[23, 24] Ischemia insults initiate to produce a large amount of free 
radicals and result in neuronal cell death, BBB disruption and neurological 
deficits.[25] Growing evidences suggest that ROS can mediate autophagy via 
posttranslational modification of biomolecules including proteins, lipids and DNA in 
ischemic stroke.[26, 27] However, the roles and underlying mechanisms of 
RNS-mediated autophagy in ischemic stroke have yet received enough attention.  
In this article, we review current progress regarding the roles of autophagy in the 
pathological process of cerebral ischemia/reperfusion (I/R) injury. In particular, we 
emphasize on the roles of RNS in regulating autophagy and their potential impacts on 
developing novel therapeutic approaches for ischemic stroke.  
 
2. Autophagy in ischemic stroke 
2.1 Detection of autophagy activation in ischemic brain 
Autophagy can be evaluated through the detection of multiple autophagic markers in 
each step or direct morphology observation of autolysosomes.[20] Increased 
expression of Beclin 1 and LC3-II often serve as useful markers to indicate 
autophagosomes formation. Especially, labeling LC3 is commonly applied to track 
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autophagosomes by observing its distribution change from uniform residence to 
punctate dots.[28] Moreover, p62/SQSTM1 has multiple domains mediating its 
interaction with relevant binding partners and functions as an autophagy receptor for 
selective degradation of ubiqutinated substrates.[29] Accompanying with the 
degradation of substrates, p62/SQSTM1 is also digested within autolysosomes. Thus, 
decreased p62/SQSTM1 level could be an indicator for autophagy maturation and 
degradation.[30] LC3 and p62/SQSTM1 have been documented to be specific and 
reliable autophagy markers in formalin fixed and paraffin embedded human tissues 
for immunohistochemistry.[31] With the progress of the mechanisms, we believe that 
more and more specific autophagy biomarkers would be discovered in future.  
The activation of autophagy in ischemic stroke has been intensively studied. 
Autophagic flux was not only reported in ischemic brains of experimental stroke 
rodent models with morphological evidences and changes of autophagic markers [32], 
but also in the brains of ischemic stroke patients with increased levels of Beclin 1 and 
LC3 in cerebrospinal fluid and serum [33]. The appearance of autophagic vesicles has 
been also found in human post-mortem brain tissue after stroke.[34] After ischemic 
insults, autophagic flux not only occurs in neurons [35], but also astrocytes [36] and 
endothelial cells [37]. Thus, autophagy could be a critical player in the pathological 
process of ischemic brain injury which involves multiple cells at different stages of 
ischemic stroke. 
2.2 Controversial roles of activated autophagy in ischemic brain injury 
No consensus about the roles of activated autophagy in ischemic stroke is documented 
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in current stage of the investigations. Yet, two things are irrefutable. One is that 
increased autophagy occurs in the brain in response to ischemic injury; the other is 
that basal level autophagy is indispensable for keeping brain function. Since these 
opinions are widely discussed elsewhere, we will not further elaborate here.[21, 38] It 
has been an intractable thematic since last decades whether the induction of 
autophagy benefits for cell survival or promotes cell death in cerebral ischemia injury. 
Existing divergent data, like ‘muddied the water’, bring the complexity and challenge 
to evaluate the roles of activated autophagy in the pathological process of ischemic 
stroke. However, like pieces of the puzzle, they also provide clues to objectively 
understand these opposite outcomes. Growing evidences suggest that the final cell 
fate partly depends on the game between autophagy demand for substrate removal 
with cell affordability (autophagy is a adenosine triphosphate (ATP)-dependent 
process).[39] Thus, it is understandable that many controversial results about the roles 
of autophagy have been reported in the experiments with different protocols. For 
better understanding those divergent results, we should consider following factors in 
data interpretation about the effects played by activated autophagy in ischemic stroke.  
2.3 Potential factors responsible for divergent roles of autophagy 
Table 1 shows controversial results about the effects of autophagy on ischemic brain 
in literatures with different protocols. Those results appear to be confusing, but 
opportunity often disguises as challenge. Stark contrast studies described in the Table 
1 bring a big challenge to understand the real roles of autophagy in ischemic stroke. 
On the other hand, they also pave the way for finding the potential factors and 
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developing therapeutic strategies for improving outcomes. In the light of this point, 
herein, we carefully review detail protocols, experimental results and conclusions 
about the roles of autophagy in those animal models. Following factors should be 
considered in the experimental designs and results interpretation.  
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Table1: Dual roles of autophagy in ischemic brain injury in current literatures 
Role of autophagy Model Treatment Dose Timing  Route Reference  
Detrimental 
SD rats MCAO 
I30min/R24h 
3-MA 600nmol at the onset of reperfusion i.c.v. [40] 
Detrimental 
SD rats MCAO 
 I2h/R24h 
3-MA 400nmol 
40min before the onset of 
reperfusion 
i.c.v. [41] 
Detrimental 
SD rats MCAO  
I2h/R24h 
3-MA 600nmol at the onset of reperfusion i.c.v. [42] 
Detrimental 
SD rats MCAO 
I2h/R72h 
Tat–Beclin-1 15mg 24 and 48h after MCAO i.p. [43] 
Detrimental SD rats pMCAO 3-MA 300/600nmol 10min after pMCAO i.c.v. [44] 
Detrimental SD rats pMCAO 
3-MA  
BFA 
Z-FA-fmk 
150-600nmoL 
4nmol 
13-26nmol 
after the onset of pMCAO i.c.v. [45] 
Detrimental 
C57BL/6 mice 
pMCAO 
3-MA 
Rapa 
60μg 
100μg 
10min after pMCAO i.c.v [46] 
Detrimental 
C57BL/6 mice 
pMCAO 
3-MA 60μg after the onset of pMCAO i.c.v. [47] 
Detrimental 
SD rats 
20min global 
ischemia 
3-MA 600nmol 
30 min/60min before ischemia 
60min after reperfusion 
i.c.v. [48] 
Detrimental 
SD rats MCAO 
I2h/R24h 
3-MA 50nM before MCAO 
stereotaxic 
injections 
[49] 
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Role of autophagy Model Treatment Dose Timing  Route Reference  
Detrimental 
SD rats MCAO 
 I90min/R24h 
PcDNA plenti6.3-Bec 
LY294002 
- 
10mg/kg 
30min before MCAO 
i.c.v. 
i.p. 
[18] 
Detrimental 
SD rats MCAO 
I1h/R 
3-MA 600nmol 1h before MCAO i.c.v. [50] 
Beneficial  
SD rats MCAO 
I90min/R72h 
LY294002 15μM 30min before MCAO i.c.v. [51] 
Beneficial 
SD rats MCAO 
I2h/R22h 
LY294002 15μM 30min before MCAO i.c.v. [52] 
Beneficial 
SD rats MCAO 
I2h/R22h 
3-MA 
Rapa 
Li2CO3 
0.15mg/kg 
150μg/kg 
20mg/kg 
0.5h before MCAO i.v. [53] 
Beneficial 
SD rats  
pMCAO 
3-MA 200nmol 24h before pMCAO i.c.v. [54, 55] 
Beneficial 
SD rats  
pMCAO 
3-MA 
BFA 
Rapa 
100-400nmol 
4nmol 
8.8-35pmol 
24h before pMCAO i.c.v. [56] 
Beneficial 
Mice 
pMCAO 
3-MA 60μg 30min before MCAO i.c.v. [57] 
Beneficial 
C57BL/6 J mice 
MCAL 
eMCAO 
Rapa 
chloroquine 
0.625-2.5mg/kg 
30-90mg/kg 
after the onset of ischemia; 
24h post-stroke 
i.p. [58] 
(p)MCAO: (permanent) middle cerebral artery occlusion; I: ischemia; R: reperfusion; 3-MA: 3-Methyladenine; i.c.v.: intracerebroventricular; i.p.: intraperitoneal; BFA: 
 bafilomycin A; Rapa: rapamycin; eMCAO: embolic MCAO; MCAL: middle cerebral artery ligation. 
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2.3.1 Therapeutic timing of autophagy regulators  
Autophagy is a dynamic regulatory process and its roles depend on different phases of 
ischemia. Thus, we screen and analyze relevant studies with similar experimental 
protocols and pay special attention on the intervening time points of autophagy 
regulators in both rat models [44, 45, 54-56] and mouse models [46, 47, 57]. It is 
obvious that administration timing of autophagy regulators could be a critical factor to 
different outcomes. In other words, therapeutic time points could determine the 
outcomes of autophagy regulation. Interestingly, the claimed beneficial effects of 
autophagy on ischemic brain were commonly reported in the literatures with the 
administration of autophagy inhibitors or activators prior to ischemic insults.[51-57] 
In contrast, evidences supporting the detrimental roles of autophagy in ischemic brain 
were often obtained from the literatures using autophagy regulators after the onset of 
ischemic insults or at the phase of reperfusion.[40-47] Those studies indicate that 
autophagy activation could be an attempt for survival at early stage of cerebral 
ischemia, but those self-defensive functions might be pinned down by serious 
damages attributed by ischemia plus reperfusion. In another word, reperfusion after 
ischemia might be a turning point transferring autophagic roles from protective to 
destructive. Importance of intervening timing inspires to select proper therapeutic 
time point for better outcomes. 
2.3.2 Autophagy inhibitor or activator  
To date, efforts have been made for searching a single silver bullet for autophagy 
regulation, like finding a fitting shoe for Cinderella.[59] But, no one is perfect yet. For 
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autophagy inhibition, it could be executed by pharmacologic inhibitors or 
knockdown/knockout of specific proteins like Beclin 1, LC3, Atgs of autophagy 
pathways.[59, 60] It appears that genetic mutation animal models might not be ideal 
choices for autophagy studies because autophagy is a dynamic process. The mutation 
for specific genes in autophagy signal pathways would be far beyond the clinical 
scenario. Actually, PI3K inhibitors, like 3-methyladenine (3-MA), LY294002 and 
wortmannin could be good tools for autophagy suppression because those agents 
could inhibit the formation of autophagosomes.[59] Besides, the other common used 
inhibitors such as bafilomycin A1 [61] and chloroquine [62] were revealed to prevent 
autophagosome-lysosome fusion to impede autophagy at the later phase. Nevertheless, 
there is still no an ideal autophagy inhibitor. Let us take 3-MA as an example. As the 
first generation of autophagy inhibitor, 3-MA has been widely used for autophagy 
study.[63] However, a recent report claimed that nutrition state had great impacts on 
the effects of 3-MA. Under nutrient-rich condition, the prolonged treatment of 3-MA 
(up to 9 h) promoted cellular autophagic flux whereas 3-MA reversely inhibited 
autophagy under nutrient starvation.[64] The dual roles of 3-MA in autophagy might 
be due to its different temporal effects on class I and class III PI3K. Moreover, 3-MA 
was also reported to modulate non-autophagic pathway including activation of PKA 
[65] and inhibition of NF-kB pathway [49]. Therefore, great cautions should be noted 
in data interpretation when these inhibitors are used for autophagy studies. As for 
autophagy induction, rapamycin and RAD001 (a rapamycin-derivative), are 
commonly used to enhance autophagy via inhibiting mTOR.[66] Yet, mTOR 
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inhibitors lack specificity which only partially affect mTOR signaling. The mTOR 
inhibitors could also activate AKT whilst repressing mTOR.[67, 68] Thus, we should 
be very cautious in data interpretation when those autophagy regulators are used in 
the experiments.  
2.3.3 Drug dose, therapeutic route and others 
Besides, drug dose and therapeutic route could also lead to controversial results. For 
example, 3-MA is typically used as an autophagy inhibitor at a working concentration 
at 5mM. However, a recent study reported that 3-MA at 2.5mM did not show 
inhibitory effects on basal level of autophagy, but reversely triggered autophagic 
flux.[69] Thus, we should pay attention to the concentrations or doses of autophagy 
regulators used in those studies. With the same drug, the outcomes could be different 
when different doses are designed for autophagic regulation. It is necessary to further 
evaluate the roles of autophagy in ischemic stroke experiments with the concentration 
of 3-MA at 50nM or lower.[49] Besides the drug concentration, administration route 
might be another factor should be concerned. In most cases, pharmacologic agents 
were directly injected into cerebral lateral ventricle in order to minimize the side 
effects and improve the bioavailability. Meanwhile, some cases applied intraperitoneal 
or intravenous injection for agent administration.[18, 43, 58] Naturally, the effects of 
drugs on peripheral system must be taken into consideration. Pharmacokinetics and 
pharmacodynamics of the drugs may also create the potential problems. Thus, it is 
understandable that regulating autophagy with the same agents could yield different 
outcomes.[18, 51] Moreover, different cerebral ischemia models with or without 
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reperfusion could also induce divergent results.[50, 54, 55] In short, divergent data 
about the roles of autophagy in ischemic stroke might depend on multiple factors 
including intervening time point, specificity of autophagy regulators, and 
administration dose and route, etc.   
2.4 Autophagy and cell death 
It is self-evident that autophagy activation can play different roles in specific ischemia 
scenarios. Beyond this, knowledge is still limited on how autophagy alters cell fate to 
“blind alley”. Herein, we review the progress of autophagy-induced cell death, 
providing insights to develop novel therapeutic strategies for ischemic stroke.   
Autophagy can induce different forms of cell death under intensive stress condition 
like cerebral I/R injury. Merely the presence of autophagy in a dying cell does not 
equate to autophagic cell death.[70] To avoid confusion, the term of ‘autophagic cell 
death’ has been redefined by the Nomenclature Committee on Cell Death (NCCD). It 
was described to be inhibited by genetic mutating at least two molecules of autophagy 
pathways.[71] Autosis, a novel form of autophagy-dependent and non-apoptotic cell 
death has been identified, which is characterized by dilated and fragmented ER, ER 
disappearance, nuclear membrane convolution and focal swelling of the perinuclear 
space.[72] Furthermore, this type cell death highly depends on Na+, K+-ATPase.[73] It 
was revealed that autotic cell death occurred in neurons of hippocampal CA3 area in 
the absence of apoptosis and necrosis during cerebral hypoxia-ischemia.[73] 
Presumably, autosis paves the way for us to understand that autophagy has a causative 
link with cell death instead of only presence in dying cells. 
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It appears to be that unfavorable effects of autophagy on ischemic brain are partially 
attributed by triggering programmed cell death (PCD) to passive cell death.[74] 
Ischemic stroke is characterized with the interruption of cerebral blood flow to induce 
brain damage including cell death. Indeed, necrosis and PCD such as apoptosis have 
been intensively investigated under ischemic insult.[75] Necrosis predominates in the 
ischemic core of prompt blood flow blockage. It often occurs within several minutes 
triggered by abrupt ATP depletion. Morphologically, it is distinguished by the features 
of vacuolation in cytoplasm, plasma membrane breakdown and induction of 
inflammation.[76] In general, necrosis is considered as an irreversible and 
uncontrolled form of cell death like “a falling knife”. However, the cells in the 
penumbra of blood flow reduction often initiate PCD in order to minimize cerebral 
injury.[77] PCD could be interpreted as last attempt for survival in dying cells, which 
at least provides therapeutic time window to intervene.[78] With the development of 
new techniques and high-resolution tools, new types of PCD including necroptosis 
[79], pyroptosis [80] and ferroptosis [81] have been observed and identified. Next, we 
discuss how autophagy alters cell fate through changing the types of cell death. It is 
widely accepted that necrosis, apoptosis and activated autophagy often coexist in the 
penumbral region. Intracellular ATP level plays a determining role in switching cell 
death phenotypes from apoptosis to necrosis.[82] Of note, autophagy activation 
aggravates ATP depletion by excessive removal of damaged but still functional 
mitochondria and its own consumption.[83, 84] Especially, neurons are vulnerable to 
ATP depletion due to its high energy demand. Thus, autophagy might be a switch in 
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the decision between apoptosis and necrosis via ATP consumption in ischemic brain.  
 
3. Mitophagy in ischemic stroke 
3.1 Activation of mitophagy-a selective autophagy in ischemic brain   
Mitochondrial autophagy, also termed mitophagy, is identified by autophagosomes 
around mitochondria, recruiting LC3-II to degrade the depolarized mitochondria.[85] 
Besides generating more than 60% of cellular ATP via oxidative phosphorylation, 
mitochondria are also widely involved in regulating redox signaling and PCD 
pathways. Therefore, quality control of mitochondria is critical for cellular 
homeostasis of brain. Under cerebral I/R injury, damaged mitochondria can be 
divided into functionally uneven two parts. Then, the daughter mitochondria with 
decreased membrane potential are removed by autophagy.[86] As it turns out, 
mitophagy is of importance to neurons because of their high dependence on 
mitochondrial function. Multiple signaling pathways and molecules are involved in 
recognizing damaged mitochondria for selective degradation. Mitophagy could be 
majorly mediated by PINK1/Parkin pathway in ischemic stroke.[38] In detail, once 
mitochondrial potential dramatically decreases, PINK1 as a sensor of potential, will 
translocate from inner mitochondrial membrane to outer mitochondrial membrane 
(OMM). Subsequently, PINK1 in OMM will further recruit Parkin from cytosol to 
damaged mitochondria, initiating autophagic machinery. In addition to 
Parkin-dependent pathway, receptors located in OMM including NIX [87], BNIP3 [88] 
and FUNDC1 [89], have also been reported to trigger mitochondrial removal by 
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autophagosomes via interaction with LIR motif of LC3 under hypoxia condition. 
Recent studies also indicate that Ambra1, Cardiolipin and SMURF1 could participate 
in mitophagy through serving as novel receptors to recruit the phagophores expanding 
to mitochondria.[90-92] Thus, mitophagy is a complex regulatory system to monitor 
mitochondrial quality for cell survival. 
3.2 Dual roles of mitophagy in cerebral ischemia injury 
Like autophagy, the roles of mitophagy in ischemic brain still remain obscure. 
Mitophagy activation has been reported in different experimental conditions including 
middle cerebral artery occlusion (MCAO) animal models and oxygen-glucose 
deprived (OGD) neuronal and endothelial cell models.[53, 93] It is noteworthy that 
activated mitophagy is mainly evident in neurons undergoing ischemia [93, 94], 
although astrocytes are also documented [95]. Mitophagy is essential to brain function 
via timely eliminating damaged mitochondria, which produce lots of free radicals, 
release cytochrome c and activate apoptosis pathway.[96, 97] In cerebral ischemia 
model, rapamycin attenuated cellular dysfunction via activating mitophagy, which 
was reversed by 3-MA.[98] However, a contrary opinion claimed that mitophagy 
might exacerbate brain damage under intensive ischemia stress.[38] Like autophagy, 
activated mitophagy also possesses dual roles in ischemic stroke: physiological level 
is indispensable for cell survival and excessive level contributes to cell death.[99, 100] 
Mitophagy must be balanced by mitochondrial biogenesis to meet brain energy 
demand, or it will be fatal to the brain, at least partly induced by intracellular ATP 
depletion. To date, the precise roles and regulation of mitophagy in ischemic stroke 
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still remain to be further clarified.  
There is still no consensus about the roles of mitophagy in cerebral I/R injury. The 
major limitations of current studies could be attributed to the lack of reliable and 
specific methods to assess mitophagy and pharmacologic modulators to specifically 
regulate mitophagy. A recent study revealed that rapamycin treatment before transient 
MCAO (tMCAO with 2h ischemia plus 22h reperfusion) attenuated cerebral I/R 
injury via enhancing mitophagy.[98] However, our unpublished data indicated 
administration of 3-MA and Mdivi-1 (an inhibitor of Drp1) at the reperfusion onset 
obviously protected brain against ischemia injury in a similar MCAO model through 
inhibiting mitophagy. These contrary results suggest reperfusion might be a turning 
point for switching the roles of mitophagy in ischemic brain. More intriguingly, 
different ischemia periods followed by reperfusion might also induce different 
mitophagic outcomes. For example, suppression of mitophagy at the onset of 
reperfusion reinforced neuronal injury in tMCAO model with 1 h ischemia plus 23 h 
reperfusion.[93] Conversely, in another tMCAO model with 6 h ischemia plus 18 h 
reperfusion, treatment of carnosine at the onset of reperfusion attenuated mitophagy, 
accompanying with the improved brain function.[100] Actually, with the critical 
importance of mitochondria in brain function, the roles of activated mitophagy in 
ischemic stroke have gained widespread attention. In the meantime, the big void in 
precise roles of mitophagy has sparked intensive interests to deeply understand 
mitophagic process and seek for intervening strategies for therapeutic benefit. 
Therefore, it is warranted to design series of studies using different cerebral I/R 
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protocols and pharmacological/genomic modulation to figure out the turning points 
and the factors switching beneficial effects to detrimental actions of mitophagy.  
 
4. Reactive nitrogen species (RNS) and autophagy 
4.1 Roles of RNS during cerebral I/R injury 
Undoubtedly, modulating autophagy/mitophagy in ischemic stroke will have a 
potential therapeutic prospect in clinical practice. Reperfusion after ischemia might be 
a switch to determine different autophagic/mitophagic outcomes. Thus, it is a wise 
choice to search and regulate key upstream signaling molecules, which majorly form 
or perform functions during reperfusion to mediate autophagy/mitophagy. 
I/R insults induce the generation of ROS and RNS, triggering numerous molecular 
cascades and resulting in brain damage.[25, 101] Thrombolytic therapy is still the 
most effective therapeutic strategy to rescue the neurons in penumbra.[102] However, 
reperfusion after ischemia alters microenvironment abruptly, inducing a large number 
of free radicals and aggravating brain injury.[103] Free radicals are mainly from the 
dysfunction of mitochondrial oxidative phosphorylation. Damaged but still functional 
mitochondria generate NADH-supported hydrogen peroxide at a rate up to 10-fold 
higher than that of intact mitochondria.[104] It is well known that mitochondria are 
not only the pools of free radicals, but major targets of oxidative/nitrosative stress. 
Once oxidative/nitrosative stress overloads cellular antioxidant capacities, it will 
induce mitochondrial dysfunction.[24] Under physiological level, ROS can serve as 
important cellular redox signals for preforming various biological functions. However, 
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excessive ROS would activate inflammation and trigger over-oxidation to induce 
brain damage. In autophagy/mitophagy, oxidative stress was thought to decline the 
mitochondrial membrane potential (ΔΨm) and trigger mitochondrial fission via 
activating Drp1, playing a critical role in PINK1/Parkin-mediated mitophagy during 
cerebral I/R injury.[105, 106] Also, ROS were reported to regulate PINK1/Parkin 
pathway to mediate cadmium-induced mitophagy.[107] The roles of ROS and their 
underlying regulatory mechanisms during autophagy/mitophagy have been 
systemically discussed in a recent review article.[108] Thus, in following session, we 
focus on the roles and regulatory mechanisms of RNS in autophagy/mitophagy during 
cerebral I/R injury.  
As representative RNS, NO and ONOO
-
 play critical roles in cell death and BBB 
disruption during cerebral I/R injury. In most cases, NO is produced from L-arginine 
and oxygen via enzymatic catalysis by three types of NOS including neuronal NOS 
(nNOS, type 1), inducible NOS (iNOS, type2), and endothelial NOS (eNOS, type 3). 
All three NOS subtypes are expressed in the brain. NO at low concentration generated 
by eNOS and nNOS acts as an indispensable messenger to regulate post- or 
pre-synaptic activities [109], cerebral blood flow [110] and inflammatory response 
[111]. Yet, excessive NO derived from iNOS and nNOS could trigger cell death and 
BBB leakage during I/R injury.[25] Our group has made great efforts to study the 
roles and mechanisms of NO in neurological deficits, neuronal cell death and BBB 
disruption in ischemic stroke. In our early study, by using electron paramagnetic 
resonance spin trapping technology and molecular biology approaches, we found that 
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NO generation had two phases in ischemic brain: The first phase of NO was generated 
from the eNOS activation at ischemia phase but the second phase of NO generation 
was from the activation and upregulation of iNOS and nNOS at the stage of 
reperfusion. At reperfusion stage, a large amount of NO was found in both ischemic 
core and penumbra of the ischemic brain. Besides, non-selective NOS inhibitor 
N  G-nitro-l-arginine methyl ester, nNOS selective inhibitor 7-nitroindazole and iNOS 
selective inhibitor l-N6-(1-iminoethyl)-lysine remarkably reduced infarction volume 
and brain damage during cerebral I/R injury.[112] Further studies indicate that 
caveolin-1, a 22 kDa integral membrane protein located at the caveolae, could be 
critical molecular target of NO.[113] In our recent studies, caveolin-1 was 
demonstrated to attenuate matrix metalloproteinases (MMPs) activity, prevent tight 
junction proteins degradation and protect the brain against ischemic injury by 
inhibiting RNS production.[114-116] Therefore, we propose that 
RNS/caveolin-1/MMPs signaling cascades could be important molecular mechanisms 
and therapeutic targets for ischemic stroke.[128-130] Accordingly, selective nNOS 
inhibitors like tirilazad [117], ARL-17477 [118] and selective iNOS inhibitors such as 
1400W [119] and aminoguanidine [120] have the potentials to be drug candidates for 
ischemic stroke treatment. Nevertheless, it is worthy to mention that NO derived from 
eNOS contributes to reduce cerebral ischemia injury, at least attributed by maintaining 
vascular physiological functions.[121, 122] Therefore, the roles of NO in the 
pathological process of ischemic stroke depend on the level of NO and its different 
sources.  
 23 
Interestingly, O2
•− and NO are simultaneously produced during cerebral I/R injury. 
The reaction of NO and O2
•− is extremely fast to generate ONOO
- 
at the 
diffusion-limited rate (1.6×1010 (mol/L)-1 s-1).[23] ONOO
-
, another representative type 
of RNS, is a crucial cytotoxic mechanism of O2
•− and NO in cerebral I/R injury. 
ONOO
-
 can diffuse across biomembranes and even possess higher diffusion 
capability than O2
•−.[123] Akin to NO, ONOO
- at physiological level possesses 
significant biological functions.[124] But, excessive ONOO
-
 triggers inflammation, 
lipid membrane peroxidation and induces mitochondrial dysfunction [125], 
subsequently exacerbating BBB disruption and brain dysfunction [126]. To date, 
detection of ONOO
-
 is still a challenging task due to the limitation of its short 
half-life. Thus, 3-nitrotyrosine (3-NT) is often used as the footprint of ONOO
-
, which 
is produced from the nitration of free tyrosine or protein tyrosine.[127, 128] Actually, 
plasma 3-NT level was revealed to have positive correlation with the magnitude of 
ischemic brain injury in stroke patients.[129] Developing effective tools to monitor 
the production of ONOO- is critical. Recently, we have successfully developed 
several novel fluorescent probes for detecting ONOO
- 
with high sensitivity and 
reliability.[130, 131] With those fluorescent probes, we directly visualized ONOO- 
production in the ischemic brain tissues and proved the capacities of several natural 
compounds to scavenge ONOO- against I/R injury.[132, 133] Targeting ONOO- could 
be an important and novel strategy for drug development for ischemic stroke. Recent 
studies by us and others indicated that peroxynitrite decomposition catalysts such as 
FeTMPyP [134, 135] and peroxynitrite scavengers like uric acid [136] could attenuate 
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infarct volume, reduce brain edema, prevent BBB leakage and decrease the risk of 
hemorrhagic transformation in experimental stroke models. Therefore, NO and 
ONOO
-
 could be critical factors contributing to cerebral I/R injury. 
4.2 Roles of RNS in autophagy/mitophagy 
As mentioned above, reperfusion might be a decision time point to determine 
different outcomes of autophagy/mitophagy. Coincidentally, a large amount of RNS 
often trigger series of cascades after reperfusion, contributing to cerebral I/R injury. 
Further evidences reveal that RNS play a role in regulating autophagy/mitophagy.[137] 
Thus, we summarize current investigations about the roles of RNS in 
autophagy/mitophagy.  
NO plays its dual roles in autophagy/mitophagy, varying with different cellular 
context. NO, as an important cellular messenger, serves as regulatory effects via 
S-nitrosylated proteins (SNO-proteins).[138] Although lots of proteins possess 
multiple cysteine residues, only specific cysteine residues could be S-nitrosylated. 
The selectivity of cysteine residues for S-nitrosylation is determined by several 
molecular factors and mechanisms, like proximal priority.[139] Besides, 
protein-to-protein transnitrosylation may be another major mechanism to generate 
SNO-proteins in vivo, during which a NO group is transferred from a donor protein to 
a selective acceptor protein.[138] Accumulating evidences suggest NO plays a role in 
modulating autophagy. Nevertheless, there still exists controversy about how NO 
affects autophagy/mitophagy.[140] One view is that NO activates 
autophagy/mitophagy, supported by emerging findings. Exposure to 
 25 
4-hydroxytamoxifen, NO was proved to be involved in the completion of pro-survival 
autophagy including autophagic vesicle formation and maturation.[141] Besides, NO 
participated in physalin A-triggered autophagy in A375-S2 cells via inhibiting mTOR 
expression.[142] This phenomenon was also observed by another investigation. NO 
caused nitrosative stress which engaged ATM/LKB1/AMPK/TSC2 signaling cascades 
to repress mTORC1 and further activate autophagy.[143] In addition, multiple 
signaling molecules like ERK [141, 144] and AMPK [145, 146] were demonstrated to 
involve in NO-induced autophagy. Intriguingly, NO also plays a critical role in 
mitochondrial fission and removal of damaged mitochondria by autophagy. One study 
illustrated that the interaction of full-length PINK1 and nNOS triggered Parkin 
translocation then induced mitophagy. Moreover, it was shown that optimum levels of 
NO were sufficient for the recruitment of Parkin to the damaged mitochondria, even 
in PINK1 deficiency.[147]  
Of note, there also exist opposite evidences to support that NO suppresses autophagy 
instead of activating. David C. Rubinsztein’s group found NO inhibited autophagy by 
suppressing the activity of S-nitrosylation substrates, like JNK1 and IKKβ. 
Overexpression of nNOS, iNOS, or eNOS also blocked autophagosome formation via 
the JNK1–Bcl-2 pathway.[148] Indeed, growing data support the inhibitory effects of 
NO in autophagy. NO affects at least two proautophagic pathways: 
JNK1/Bcl-2/Beclin 1 and IKKβ/AMPK/mTORC1 to impair autophagy via 
SNO-proteins.[140] For examples, NO was revealed to inhibit autophagy through 
mTOR activation in lipopolysaccharide-stimulated macrophages.[149] Additionally, 
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series of studies indicated that NO served as inhibitory effects on autophagy through 
suppressing JNK1 activity.[150, 151] Nitrosylated Bcl-2 triggered by NO was also 
reported to inhibit autophagic flux via stabilizing the interaction of Bcl-2 with 
Beclin-1 in lung epithelial cells.[152] Above data indicate the complex and conflictual 
effects of NO on autophagy/mitophagy. However, it should be mentioned that a 
majority of S-nitrosylated target proteins are widely involved in multiple biological 
activities under NO condition. Moreover, autophagic process often shares molecules 
with other signaling pathways like apoptosis. Thus, it is not surprising to learn that the 
effects of NO on autophagy are likely to vary with different cells and models.  
As another important component of RNS, ONOO
- 
has also been reported to regulate 
autophagy/mitophagy. ONOO
- 
modifies target proteins by the interaction of a nitro 
group (-NO2) with protein tyrosines, which leads to the change of protein 
functions.[153] Increased levels of both autophagy and 3-NT were observed in the 
hepatocytes of old rats following the heat stress, with aggravated mitochondria 
damage and reduced the expression of heat shock proteins.[154, 155] Alternatively, it 
was reported that endogenous nitrated nucleotide 8-nitro-cGMP promoted autophagic 
flux to play a crucial role in cytoprotection against bacteria.[156] Exposure to 
3-morpholinosydnonimine (SIN-1), a peroxynitrite donor, increased autophagosome 
formation and Nrf2 activation contributed to cytoprotection in human umbilical vein 
endothelial cells.[157] 
Overall, above exciting data implicate a causal link between RNS and 
autophagy/mitophagy regulation. Therefore, it promises a new therapeutic opportunity 
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in ischemic stroke via targeting RNS to modulate autophagy/mitophagy. 
4.3 RNS-mediated autophagy/mitophagy under ischemia insult 
Autophagy/mitophagy can be mediated by free radicals via posttranslational 
modification of biomolecules including proteins, lipids and DNA in ischemic 
stroke.[158, 159] With growing knowledge about the roles of ROS in initiating 
autophagy/mitophagy, emphasis has been given to the ROS-induced 
autophagy/mitophagy in ischemic brain injury.[36, 108] On the contrary, the 
importance of RNS-mediated autophagy/mitophagy in ischemic brain has yet received 
enough attention.  
At physiological level, NO functions as a ubiquitous second messenger to modulate 
signal transduction pathways and maintain normal biological activities via protein 
S-nitrosylation modification in CNS. However, under pathological condition, aberrant 
SNO-proteins induced by excessive NO often lead to protein misfolding, 
mitochondrial fragmentation and apoptosis.[139] Current advances suggest that 
aberrant protein S-nitrosylation is involved in many neurodegenerative diseases.[160] 
For example, NO induced mitochondrial fission via S-nitrosylation of Drp1, resulting 
in excessive mitophagy and neuronal cell death.[161-163] In response to nitrosative 
stress, mitochondrial fission and the autophagosomes engulfing injured mitochondria 
were observed in young neurons.[163] Alternatively, under prolonged ischemic 
condition, NO acted as an activator to induce caveolin-1-mediated claudin-5 
degradation by triggering autophagy. Moreover, NO scavenger C-PTIO and iNOS 
inhibitor 1400W obviously suppressed the delivery of claudin-5 for degradation.[164] 
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Moreover, iNOS activation also participated in upregulating autophagy of vascular 
endothelial cells, accompanying with increased apoptosis during I/R injury.[165]  
Of note, nitration of tyrosine residues is a chemically distinct redox reaction from 
S-nitrosylation of cysteine thiol, representing another protein modification via the 
reaction of tyrosine with ONOO
-
. Proteomic analysis revealed that nitration-related 
proteins included metabolism proteins, cytoskeleton proteins, chaperones and carrier 
proteins in the samples from hypoxia/reoxygenated brain tissues.[166] About 23 
proteins tyrosine nitration were identified in I/R heart and 10 of them were from 
mitochondria.[167] Interestingly, mitochondrial proteins appear to be more 
susceptible to nitration stress.[168] Then, nitrated mitochondrial proteins like 
voltage-dependent anion channels [169], electron transport chain protein subunit 
complexes I–V and heat shock protein-90 further trigger mitochondrial dysfunction 
and energy metabolism disorder.[170, 171] Besides, emerging evidence showed that 
ischemia stress induced tight junction proteins degradation and the underlying 
mechanism was at least partially contributed by ONOO
-
-mediated autophagy.[172] 
Taken together, RNS-mediated autophagy/mitophagy may play an indispensable role 
in cerebral I/R injury. Targeting RNS and its signaling pathways could bring 
therapeutic benefits for ischemic stroke. 
5. Conclusion  
As elaborated above, growing evidences support that RNS-mediated excessive 
autophagy/mitophagy contributes to cerebral I/R injury. Indeed, autophagy/mitophagy 
activation in ischemic stroke has been widely accepted in last decade. Nevertheless, 
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there still remains controversy about the beneficial or detrimental roles of activated 
autophagy/mitophagy in ischemic brain. Accumulating in vivo evidences convey an 
important message that reperfusion after ischemia may become a critical factor 
determining autophagy/mitophagy roles from neuroprotection to neurotoxicity. In 
another word, activated autophagy/mitophagy may aggravate cerebral ischemia injury 
after reperfusion. In regard to this, modulating autophagy/mitophagy after reperfusion 
could become a potential therapeutic strategy for ischemic stroke. Strikingly, a large 
amount of RNS predominate after reperfusion, leading to autophagic/mitophagic flux 
via S-nitrosylation or nitration modification of macromolecules in ischemic brain.  
Therefore, RNS would be therapeutic targets to modulate autophagy/mitopahgy in 
ischemic stroke (Figure1). Without doubt, there is still a long way to go before 
shedding this new light to clinical practice, yet it shows a potential for future ischemic 
stroke therapy. 
6. Expert opinion 
Autophagy/mitophagy activation during reperfusion after ischemia contributes to 
brain damages including neuronal cell death, BBB disruption and neurological 
deficits. Autophagy/mitophagy activation in ischemic brain has been intensively 
investigated in numerous studies. Nevertheless, existing contrary results increase the 
challenge to evaluate real roles of autophagy/mitophagy in ischemic stroke. It is 
necessary to comprehensively understand autophagy/mitophagy at first. Under strict 
inclusion criteria, we firstly screen and analyze some reports, in which either 
pharmacologic or genetic modulation of autophagy/mitophagy has been applied. 
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Excitingly, reperfusion after ischemia appears to be a turning point to determine final 
cell fate. This finding provides a potential to explain these controversial data. In 
particular, autophagy/mitophagy after reperfusion may shorten the therapeutic time 
window via accelerating intracellular ATP consumption to induce necrosis. In details, 
ATP depletion triggers transferring from ‘proactive apoptosis’ to ‘passive necrosis’, 
which exacerbates neuronal injury because of its high dependence on energy 
supply.[82]  Recently, detrimental roles of autophagy in ischemic stroke have got 
somewhat attention.[21] However, the destructive roles of mitophagy during cerebral 
I/R injury have not been adequately emphasized. Indeed, damaged mitochondria play 
a key role in metabolism disorders, energy deficiency and cell death. Correspondingly, 
mitophagy often occupies a dominant position of autophagy.[97] Thus, it is worthy to 
pay more attention on the roles of mitophagy in ischemic stroke.  
Regard to the importance of autophagic/mitophagic flux in ischemic stroke, it 
becomes a hot field to seek for critical upstream signal molecules as therapeutic 
targets. RNS might be critical in cerebral I/R injury through triggering a series of 
cellular signaling cascades and mediating excessive autophagy/mitophagy. RNS can 
act as upstream modulators to regulate autophagy/mitophagy via S-nitrosylation or 
nitration modification of specific proteins.[139, 154] Thus, it is potential to take RNS 
as novel therapeutic targets for protecting ischemic brain via regulating 
autophagy/mitophagy. Especially, ONOO
- 
is considered as a critical cytotoxic factor 
with stronger lipid membrane permeability than its parent free radicals and ONOO
- 
production could be a critical marker reflecting both oxidative and nitrosative 
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stress.[125, 126] Further investigations on the roles of ONOO
-
 and its signaling 
cascades in autophagy/mitophagy will broaden the understanding of mechanisms 
about cerebral I/R injury. With our recent breakthrough in developing the advanced 
and highly sensitive fluorescent probes for ONOO
-
 detection [130, 131], we are able 
to screen active compounds with the properties of scavenging ONOO
-
 and regulating 
autophagy/mitophagy. Targeting RNS-mediated autophagy/mitophagy and related 
signaling cascades as therapeutic strategies should be drawn great attention and 
received high priority in future researches. As analyzed in this review, autophagic 
intervening time point, specificity of autophagy regulators and so on can affect the 
results of experimental studies about the effects of autophagy/mitophagy in ischemic 
stroke. Further investigations with more restrictive protocols are desirable. 
Importantly, considering the potential inconsistence of human subjects and animal 
models, great attention should be paid to the clinical investigations on stroke patients. 
Presumably, screening circulating plasma biomarkers linking RNS-mediated 
autophagy/mitophagy with the magnitude of ischemic brain injury will bring a new 
light for clinical practice.     
Developing novel therapeutic strategies to reverse the ischemic brain injury should 
enjoy high priority in future studies. Although many neuroprotective agents have been 
reported to be effective for ischemic brain in animal experiments, no single drug is 
approved by FDA with proved clinical efficacy for neuroprotection except t-PA for 
recanalization. With enormous frustration, attentions have been moved to develop 
novel therapeutic strategies for brain repair like stem cell therapy. Although emerging 
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stem cell-based therapy has been proposed to improve neurological functions in 
pre-clinical studies [173], yet meta-analysis shows no significant effects in clinical 
practice [174]. To date, recanalization is still the most effective strategy to rescue 
neurons and improve clinical outcomes including surgical embolectomy and chemical 
thrombolysis.[175] Noteworthy, thrombolytic agent t-PA for recanalization has restrict 
therapeutic time window and the subsequent cerebral I/R injury would worsen brain 
damage, neurological deficits, and increase hemorrhagic transformation even 
mortality.[176] Recent studies by us and others provide accumulating evidences to 
support the roles of RNS in cerebral I/R injury.[126-129, 132, 134-136] 
RNS-mediated excessive autophagy/mitophagy could be an important mechanism in 
this pathological process. Thus, targeting RNS to regulate autophagy/mitophagy 
might be a promising combined therapeutic strategy for thrombolytic treatment to 
extend the therapeutic time window, improve outcomes and reduce the side effects of 
t-PA in stroke treatment. Therefore, further investigations on RNS-mediated 
autophagy/mitophagy would not only bring novel insights into the underlying 
mechanisms of cerebral I/R injury but also have a bright prospect to develop 
therapeutic strategies for ischemic stroke. 
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Article highlights 
1. Activated autophagy has double-edged roles in ischemic stroke. The beneficial or 
detrimental effects of activated autophagy on ischemic brain appear to be 
dependent on the experimental protocols with different intervening time points of 
autophagy, administration routes and doses of autophagy regulators and so forth. 
2. Reperfusion after ischemia appears to act as a critical turning point determining 
the roles of autophagy from neuroprotection to neurotoxicity via affecting 
programmed cell death. 
3. Mitophagy, as a selective autophagy, predominates in ischemic brain and also 
plays dual roles in ischemic stroke.  
4. RNS-mediated excessive autophagy/mitophagy could be an important cellular 
event contributing to cerebral I/R injury. Targeting RNS to regulate 
autophagy/mitophagy might shed new light on the therapies of ischemic stroke.  
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Table1: Dual roles of autophagy in ischemic brain injury in current literatures 
Role of autophagy Model Treatment Dose Timing  Route Reference  
Detrimental 
SD rats MCAO 
I30min/R24h 
3-MA 600nmol at the onset of reperfusion i.c.v. [40] 
Detrimental 
SD rats MCAO 
 I2h/R24h 
3-MA 400nmol 
40min before the onset of 
reperfusion 
i.c.v. [41] 
Detrimental 
SD rats MCAO  
I2h/R24h 
3-MA 600nmol at the onset of reperfusion i.c.v. [42] 
Detrimental 
SD rats MCAO 
I2h/R72h 
Tat–Beclin-1 15mg 24 and 48h after MCAO i.p. [43] 
Detrimental SD rats pMCAO 3-MA 300/600nmol 10min after pMCAO i.c.v. [44] 
Detrimental SD rats pMCAO 
3-MA  
BFA 
Z-FA-fmk 
150-600nmoL 
4nmol 
13-26nmol 
after the onset of pMCAO i.c.v. [45] 
Detrimental 
C57BL/6 mice 
pMCAO 
3-MA 
Rapa 
60μg 
100μg 
10min after pMCAO i.c.v [46] 
Detrimental 
C57BL/6 mice 
pMCAO 
3-MA 60μg after the onset of pMCAO i.c.v. [47] 
Detrimental 
SD rats 
20min global 
ischemia 
3-MA 600nmol 
30 min/60min before ischemia 
60min after reperfusion 
i.c.v. [48] 
Detrimental 
SD rats MCAO 
I2h/R24h 
3-MA 50nM before MCAO 
stereotaxic 
injections 
[49] 
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Role of autophagy Model Treatment Dose Timing  Route Reference  
Detrimental 
SD rats MCAO 
 I90min/R24h 
PcDNA plenti6.3-Bec 
LY294002 
- 
10mg/kg 
30min before MCAO 
i.c.v. 
i.p. 
[18] 
Detrimental 
SD rats MCAO 
I1h/R 
3-MA 600nmol 1h before MCAO i.c.v. [50] 
Beneficial  
SD rats MCAO 
I90min/R72h 
LY294002 15μM 30min before MCAO i.c.v. [51] 
Beneficial 
SD rats MCAO 
I2h/R22h 
LY294002 15μM 30min before MCAO i.c.v. [52] 
Beneficial 
SD rats MCAO 
I2h/R22h 
3-MA 
Rapa 
Li2CO3 
0.15mg/kg 
150μg/kg 
20mg/kg 
0.5h before MCAO i.v. [53] 
Beneficial 
SD rats  
pMCAO 
3-MA 200nmol 24h before pMCAO i.c.v. [54, 55] 
Beneficial 
SD rats  
pMCAO 
3-MA 
BFA 
Rapa 
100-400nmol 
4nmol 
8.8-35pmol 
24h before pMCAO i.c.v. [56] 
Beneficial 
Mice 
pMCAO 
3-MA 60μg 30min before MCAO i.c.v. [57] 
Beneficial 
C57BL/6 J mice 
MCAL 
eMCAO 
Rapa 
chloroquine 
0.625-2.5mg/kg 
30-90mg/kg 
after the onset of ischemia; 
24h post-stroke 
i.p. [58] 
(p)MCAO: (permanent) middle cerebral artery occlusion; I: ischemia; R: reperfusion; 3-MA: 3-Methyladenine; i.c.v.: intracerebroventricular; i.p.: intraperitoneal; BFA: 
bafilomycin A; Rapa: rapamycin; eMCAO: embolic MCAO; MCAL: middle cerebral artery ligation.
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Legend 
Figure 1. The roles of RNS-mediated autophagy/mitophagy activation in ischemic 
stroke. A large amount of RNS generate during the reperfusion following cerebral 
ischemia, triggering numerous molecular cascades and leading to cerebral I/R injury. 
RNS play critical roles in autophagy/mitophagy activation via protein 
nitrosylation/nitration modification. In detail, RNS inhibit mTOR expression to 
activate autophagy through modulating multiple signaling molecules like AMPK and 
ERK. Moreover, RNS can also trigger autophagy/mitophagy through 
nitrosylation/nitration modification of related proteins such as Drp1, PINK1 and 
8-nitro-cGMP. Activated autophagy/mitophagy has double-edged roles in ischemic 
stroke. Intriguingly, reperfusion appears to be a decision time point to transfer the 
roles of activated autophagy/mitophagy from beneficial to detrimental effects. 
